tbuckley/cabot-search huggingface dataset:
Reticulocyte Hemoglobin Content to Diagnose Iron Deficiency in Children
Authors: Carlo Brugnara
Journal: JAMA (1999)

ContextEarly identification of iron deficiency in children is essential to prevent the damaging long-term consequences of this disease.However, it is not clear which indices should be included in a diagnostic panel for iron deficiency and iron deficiency anemia in children.Objective To develop an effective approach for the diagnosis of iron deficiency and iron deficiency anemia in young children. Design and SettingRetrospective laboratory analysis, carried out over 7 weeks in 1996, using blood samples ordered by pediatricians and sent to a large metropolitan hospital for analysis.Patients A total of 210 children (mean [SD] age, 2.9 [2.0] years; 120 were male) who had a lead screening test (complete blood cell count and plasma lead level) ordered by a primary care pediatrician.Main Outcome Measures Levels of hemoglobin (Hb), iron, transferrin, transferrin saturation (Tfsat), ferritin, and circulating transferrin receptor and reticulocyte Hb content (CHr) among patients with and without iron deficiency, defined as Tfsat of less than 20%, and iron deficiency anemia, defined as Tfsat of less than 20% and Hb level of less than 110 g/L. ResultsOf the 210 subjects, 43 (20.5%) were iron deficient; 24 of these had iron deficiency anemia.Reticulocyte Hb content and Hb levels were the only significant predictors of iron deficiency (likelihood ratio test [LRT] = 15.96;PϽ.001 for CHr, and LRT = 6.59;P = .01for Hb), and CHr was the only significant multivariate predictor of iron deficiency anemia (LRT = 30.43;PϽ.001).Plasma ferritin level had no predictive value (P = .97).Subjects with CHr of less than 26 pg (optimal cutoff value based on sensitivity/specificity analysis) had lower Hb level, mean corpuscular volume, mean corpuscular Hb level, serum iron level, and Tfsat, and increased red blood cell distribution width vs those with CHr of 26 pg or more (PϽ.001for all).Conclusions Reticulocyte Hb content level was the strongest predictor of iron deficiency and iron deficiency anemia in children.It holds promise as an alternative to biochemical iron studies in diagnosis.
Abstract 4659: Phase II study of a weekly liposomal paclitaxel formulation (Genexol®-PM) and gemcitabine® combination chemotherapy in patients with advanced biliary cancer.
Authors: Keon UK Keon Uk, Jin Young Kim, Young Rok Do, Hong Suk Song, Young June Jeon, Hun Mo Ryoo, Sung Hwa Bae, Jong Gwang Kim, Jin Ho Baek, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Yoon Young Cho
Journal: Cancer Research (2013)

Abstract OBJECTIVE: Advanced biliary cancer is associated with a poor prognosis due to wide resistance to chemotherapeutic agents. This phase II clinical trial was conducted to determine the efficacy and safety of weekly gemcitabine and liposomal paclitaxel in patients with unresectable of metastatic biliary cancer. METHODS: The eligibility criteria were patients 1) with pathologically proven biliary cancer, 2) with an ECOG performance status 0 to 2, 3) aged more than 18, 4) with measurable lesions, 5) with adequate hematologic, renal and liver functions, and 6) who provided written informed consent. Each treatment cycle was consisted of gemcitabine 1000 mg/m² and liposomal paclitaxel (Genexol-PM)100 mg/m² on days 1, 8 followed by rest perioid of 14 days. It was repeated until the appearance of disease progression or unacceptable toxicity up to maximal 10 cycles. The primary end point of this study was reponse rate, and secondary end points included toxicity, progression free survival and overall survival. RESULTS: Forty five patients were enrolled; median age was 63 years; male (n=33) and female (n=12). The median number of cycles administered was 4.0 (range,1-10). Thirty nine patients were assessable for efficacy. Ten partial responses and 18 stable diseases were confirmed. Giving an overall response rate was 25.6% and disease control rate was 71.8% in per-protocol population. The median time to progression and median overall survival was 4.0 (95% CI; 3.17∼4.83) months and 8.13 (95% CI; 4.76∼11.51) months, respectively. MUC4 expression was not significantly correlated with overall survival and progression free survival (p=0.391). CONCLUSION: Weekly gemcitabine combined with Genexol-PM® appears to be effective against advanced biliary cancers. Further randomized trials are needed to confirm this finding. Citation Format: Keon Uk Keon Uk, Jin Young Kim, Young Rok Do, Hong Suk Song, Young June Jeon, Hun Mo Ryoo, Sung Hwa Bae, Jong Gwang Kim, Jin Ho Baek, Yee Soo Chae, Min Kyoung Kim, Kyung Hee Lee, Yoon Young Cho. Phase II study of a weekly liposomal paclitaxel formulation (Genexol®-PM) and gemcitabine® combination chemotherapy in patients with advanced biliary cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4659. doi:10.1158/1538-7445.AM2013-4659
Methicillin-Resistant Staphylococcus aureus
Authors: J. GLENN MORRIS
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 August 1983Methicillin-Resistant Staphylococcus aureusJ. GLENN MORRIS JR., M.D., JAMES H. TENNEY, M.D.J. GLENN MORRIS JR., M.D.Search for more papers by this author, JAMES H. TENNEY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-99-2-283_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: A recent article on methicillin-resistant Staphylococcus aureus endocarditis by Levine and associates (1) suggested that combination therapy with rifampin and vancomycin should be used with caution, in part because of the in-vitro antagonism which has been noted between the two drugs (2, 3). We report a case of methicillin-resistant S. aureus endocarditis in which in-vitro antagonism was present, but in which an apparent bacteriologic cure was obtained only after therapy with both rifampin and vancomycin.A 73-year-old man with a prosthetic aortic valve became febrile (103.6 °F) 24 hours after a transurethral resection (for which he had...References1. LEVINECUSHINGJUIBROWN DRJW. Community-acquired methicillin resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med. 1982;97:330-8. LinkGoogle Scholar2. WATANAKUNAKORNGUERRIERO CJ. Interaction between vancomycin and rifampin against Staphylococcus aureus. Antimicrob Agents Chemother. 1981;19:1089-91. CrossrefMedlineGoogle Scholar3. ZINNERLAGASTKLASTERSKI SHJ. Antistaphylococcal activity of rifampin with other antibiotics. J Infect Dis. 1981;144:365-71. CrossrefMedlineGoogle Scholar4. LOBOMANDELL MG. Treatment of experimental staphylococcal infection with rifampin. Antimicrob Agents Chemother. 1972;2:195-200. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: School of Medicine University of Maryland Baltimore, MD 21201 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1983Volume 99, Issue 2Page: 283-284KeywordsAortic valveDrug therapyEndocarditisMethicillin-resistant Staphylococcus aureusVancomycin Issue Published: 1 August 1983 PDF DownloadLoading ...
Ten-year survey of treatment with implanted cardiac pacemaker.
Authors: E Sowton, G Hendrix, P Roy
Journal: BMJ (1974)

Since the first implant of an artificial cardiac pacemaker in a patient by Senning in 1958 the reliability of apparatus has in creased considerably and the indications for long-term pacing have greatly extended. In this paper we present the clinical results obtained in 372 patients attending the pacing clinic at Guy's Hospital up to 31 December 1973. Particular reference is made to the changes in indications in recent years and to the reliability of present apparatus.
The Molecular Biology of RNA Tumor Viruses: A Physician's Guide
Authors: J. Michael Bishop
Journal: New England Journal of Medicine (1980)

The possibility that certain tumor viruses are simply laboratory artifacts makes them in some respects more interesting rather than less, because it means that they may be offering us a way of isolating and studying the genes responsible for the cancerous state. That seems to be the real justification for putting so much effort into investigating the tumor viruses, not the vague hope that human cancer will turn out to be a virus disease.1 RNA tumor viruses (or "retroviruses") are proved agents of oncogenesis in certain species.2 It is therefore not surprising that in recent years there has been a . . .
BBC programme gave distorted facts about ADHD study
Authors: C. Dyer
Journal: BMJ (2010)

The BBC has been forced to broadcast an apology and correction after its independent watchdog, the BBC Trust, found it guilty of inaccurately reporting the results of a major US study on the treatment of attention deficit hyperactivity disorder (ADHD).

The BBC’s flagship current affairs television programme Panorama included an interview with one of the study’s authors, William Pelham, who …
Right to choose
Authors: M. White
Journal: BMJ (1995)

Number ofpredicted events peryear in Oxfordshire when age specific parameters usedfor serum testing Down's syndrome Amniocentesis Programme costs Miscarriages induced by No Per case ofDown's amniocentesis Unaffected Cases carried Miscarriages Total syndrome detected per case of Screening policy births Births Miscarriages detected out induced (IJOOO) (£°°°O) Down's syndrome detected Offerserumtestingtoallpregnantwomen
Effects of Hormone-Replacement Therapy on Fibrinolysis in Postmenopausal Women
Authors: Kwang Kon Koh, Rita Mincemoyer, Minh N. Bui, Gyorgy Csako, Frank Pucino, Victor Guetta, Myron Waclawiw, Richard O. Cannon
Journal: New England Journal of Medicine (1997)

Plasma levels of plasminogen-activator inhibitor type 1 (PAI-1), an essential inhibitor of fibrinolysis in humans, increase in women after menopause, and this may contribute to the risk of cardiovascular disease. We studied the effects of hormone-replacement therapy on PAI-1 levels.
Ethics committees: impediments to research or guardians of ethical standards?
Authors: A. E While
Journal: BMJ (1995)

In 1991 the Department of Health issued a memorandum that required everydistrict health authority to establish a research ethics committee.1 Before this memorandum considerable diversity in the practice of ethics committees had been noted.2 3

A research study focusing on the needs of and provision of care to children who might be expected to die during childhood was commissioned by the Department of Health. Parents of such children who were resident in four selected regional health authorities recruited themselves to the study through advertisements in voluntary group …
Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta.
Authors: J B Allen, H L Wong, P M Guyre, G L Simon, S M Wahl
Journal: Journal of Clinical Investigation (1991)

Monocytes in the circulation of normal individuals express two receptors for the constant region of immunoglobulin, Fc gamma RI and Fc gamma RII. In contrast, we have observed that AIDS monocytes express significant levels of a third Fc gamma R, Fc gamma RIII (CD16), which is normally associated with activation or maturation of the monocyte population. By dual-fluorescence analysis using a monoclonal antibody specific for Fc gamma RIII (MAb 3G8), 38.5 +/- 3.2% of the LeuM3 (CD14)-positive monocytes in AIDS patients were CD16 positive as compared to 10.4 +/- 1.0% for healthy individuals (n = 29; P less than 0.005). Furthermore, AIDS monocytes expressed Fc gamma RIII-specific mRNA which is expressed minimally or not at all in control monocytes. As a recently identified inducer of Fc gamma RIII expression on blood monocytes, transforming growth factor-beta (TGF-beta) was found to be elevated in the serum and/or plasma of AIDS patients. Moreover, incubation of normal monocytes with AIDS serum or plasma induced CD16 expression which correlated with serum TGF-beta levels (r = 0.74, P less than 0.001) and was inhibited with a neutralizing antibody to TGF-beta. Thus, the increased CD16 expression on peripheral blood monocytes in AIDS patients may be the consequence of elevated circulating levels of the polypeptide hormone TGF-beta.
TCT-353 Pathologic Intimal Thickening Plaque Phenotype - Not As Innocent As We Though. Study With 3D Intravascular Ultrasound And Virtual Histology
Authors: Tomas Kovarnik, Zhi Chen, Andreas Wahle, Hana Skalicka, Ales Kral, Stepan Jerabek, Milan Sonka, Jan Horak, Ales Linhart
Journal: Journal of the American College of Cardiology (2014)
Transjugular Approach to Liver Biopsy and Transhepatic Cholangiography
Authors: Josef Rösch, Paul C. Lakin, Ruza Antonovic, Charles T. Dotter
Journal: New England Journal of Medicine (1973)

The percutaneous transjugular approach to liver biopsy and cholangiography (of Hanafee and Weiner) eliminates the necessity for traversing the peritoneal cavity and puncturing the liver capsule. The liver parenchyma is entered through the wall of a hepatic vein by a needle inserted into a catheter introduced percutaneously via the internal jugular vein. This approach offers a safe means for liver biopsy and transhepatic cholangiography in the patient with a bleeding tendency, high-grade obstructive jaundice or ascites. Acute cholangitis is the principal contraindication of this approach. The transjugular approach was used in 61 patients. Both biopsy and cholangiography were done in 36 patients, liver biopsy alone in eight patients, and cholangiography alone in 17 patients. Diagnostic biopsy specimens were obtained in 39 patients (89 per cent). Cholangiography succeeded in 29 of 31 patients (93 per cent) with enlarged intrahepatic ducts. There were no major complications. (N Engl J Med 289:227–231, 1973)
Pregnancy outcomes in women with thalassemia in North America and the United Kingdom
Authors: Alexis A. Thompson, Hae‐Young Kim, Sylvia T. Singer, Elliott Vichinsky, Jennifer Eile, Robert Yamashita, Patricia J. Giardina, Nancy Olivieri, Nagina Parmar, Felicia Trachtenberg, Ellis J. Neufeld, Janet L. Kwiatkowski
Journal: American Journal of Hematology (2013)

Improved survival in thalassemia has refocused attention on quality of life, including family planning. Understanding the issues associated with infertility and adverse pregnancy outcomes may impact clinical care of patients with thalassemia. We report the number and outcomes of pregnancies among subjects enrolled in Thalassemia Clinical Research Network (TCRN) registries and examine variables associated with successful childbirth. We identified 129 pregnancies in 72 women among the 264 women, age 18 years or older in our dataset. Over 70% of pregnancies resulted in live births and 73/83 (88%) of live births occurred at full term. Most pregnancies (78.2%) were conceived without reproductive technologies. Most (59.3%) pregnancies occurred while on chronic transfusion programs, however only 38.9% were on iron chelation. Four women developed heart problems. Iron burden in women who had conceived was not significantly different from age- and diagnosis-matched controls that had never been pregnant. There was also no difference in pregnancy outcomes associated with diagnosis, transfusion status, diabetes or Hepatitis C infection. Pregnancies occurred in 27.3% of women with thalassemia of child-bearing age in the TCRN registries, a notable increase from our previous 2004 report. With optimal health maintenance, successful pregnancies may be achievable.
The Hassle Factor
Authors: John G. Meharg
Journal: Annals of Internal Medicine (1992)

Letters1 November 1992The Hassle FactorJohn G. Meharg Jr., MDJohn G. Meharg Jr., MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-117-9-797_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: With the recent emphasis on "the hassle factor" in Internal Medicine, I offer, with due respect to David Letterman, a list of factors that do not usually get published.Things Primary Care Physicians Do Well that Nobody Else Can Do10) Write jury duty and airline refund excuse letters9) Fill out drivers license forms8) Certify medical necessity7) Complete life insurance forms6) Compose special bus transportation privileges letters5) Support issuing handicapped license plates4) Perform rectal exams that subspecialists do not have time for3) Sign nursing home verbal orders and death... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: 11 East Lancaster Avenue Shillington, PA 19607 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLate to the Feast: Primary Care and US Health PolicyHealth Care Rationing Affecting Older Persons 1 November 1992Volume 117, Issue 9Page: 797-797KeywordsNursing homesSub-specialty care Issue Published: 1 November 1992 PDF downloadLoading ...
The Power to Love: A Psychic and Physiologic Study of Regeneration
Authors: Edwin W. Hirsch
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pressure to work during short periods of sickness should be seen in perspective
Authors: R. M. Preece
Journal: BMJ (2011)

Aim: To investigate whether tumor-infiltrating lymphocyte (TIL) scoring based on <sup>18</sup>F-fluorodeoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) can predict the pathological response to neoadjuvant chemotherapy. Patients and Methods: A total of 261 patients with breast cancer underwent complete resection after neoadjuvant chemotherapy. PET-TIL score was calculated using tumor size, Ki-67 labeling index, and maximum standardized uptake value (SUVmax) on FDG PET/CT. The efficacy of the PET-TIL score in predicting the pathological complete response (pCR) was retrospectively evaluated. Results: pCR rates were 11.4%, 58.6%, and 38.8% in luminal, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer, respectively. The corresponding median PET-TIL scores were 28, 37, and 45. pCR rates were 20.0% and 44.2% in the low and high PET-TIL score groups, respectively (p&lt;0.001). HER2-positive and triple-negative subtypes and high PET-TIL score were independent predictors for pCR. Conclusion: PET-TIL score can predict pCR after neoadjuvant chemotherapy in breast cancer.
Bacillary angiomatosis of acquired immunodeficiency syndrome: Case report and literature review
Authors: F. Jimenez-Acosta, Rube J. Pardo, Robert J. Cohen, Edwin W. Gould, Neal S. Penneys
Journal: Journal of the American Academy of Dermatology (1990)

We report a case of bacillary angiomatosis of acquired immunodeficiency syndrome, so that dermatologists might become more aware of this easily treatable disease .A brief review of the literature is included .
Abstract 1570: Silibinin inhibits invasive properties of human breast cancer cell line MDA-MB-231 through suppression of cathepsin B and extracellular signal-regulated kinase-mediated induction of matrix metalloproteinase 2 and 9
Authors: Mohammad R. Nejati, Majid Momeny, Seyed H. Ghaffari, Majid Mojarrad, Amir H. Emami
Journal: Cancer Research (2010)

Abstract The purpose of the current study is to evaluate the effects of silibinin on human breast adenocarcinoma MDA-MB-231 cells. BrdU cell proliferation assay, Cell-based extracellular signal-regulated kinase (ERK) 1/2 activation assay, cathepsin B activity assay, Gelatin zymography and quantitative real-time RT-PCR were employed to appraise the effects of silibinin on DNA synthesis, ERK 1/2 phosphorylation, cathepsin B activity and gelatinolytic activity in MDA-MB-231 cells. Silibinin inhibited cell proliferation, ERK 1/2 activation, cathepsin B enzymatic levels and gelatinase activity in a dose-dependent manner. In addition, an expressive decrease in mRNA levels of cathepsin B, hyaluronidase-2 (Hyal-2), urokinase plasminogen activator receptor (uPAR), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) coupled with a significant induction in transcriptional levels of tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), Stefin A and Lipocalin 2 were observed. Altogether, these issues show for the first time that silibinin treatment could trammel cell growth and invasive features of a highly invasive human breast cancer cell line, MDA-MB-231, through suppression of ERK 1/2 both directly (through impeding ERK 1/2 phosphorylation) and indirectly (via transcriptional enhancement of Lipocalin 2). Furthermore, cramping enzymatic activity of cathepsin B by silibinin might cripple activation of gelatinases and thereby, reduces invasive potential in MDA-MB-231 cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1570.